You are about to leave the Clinical Value website now.
This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic hepatitis B patients in China.
Leung MK, Ko M, Chen J, Garay OU, Leung B, Chow C, Li E, Wu JTK, Yuen MF, Zheng Q…
This review highlights promising candidate biomarkers and biomarker panels that have completed phase II evaluation for the early detection of HCC.
Parikh ND, Mehta AS, Singal AG, Block T, Marrero JA, Lok AS…
This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic hepatitis B patients in China.
Chen W, Nan YM, Garay U, Lu X, Zhang Y, Xie L, Niu Z…
These latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.
Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK…
This study was designed to investigate the potential role of PIVKA-II as a diagnostic, non-invasive marker for HCC at its early stages and to assess its sensitivity and specificity as compared with the usual recommended marker AFP.
Zakhary NI, Khodeer SM, Shafik HE, Abdel Malak CA…
This white paper, which was developed by a group of experts in biomarker development, provides a framework on best practices to design, execute, and interpret biomarker studies for risk stratification, early detection, diagnosis, prognostication, and treatment response assessment in HCC.
Singal AG, Hoshida Y, Pinato DJ, Marrero J, Nault JC, Paradis V, Tayob N, Sherman M, Lim YS, Feng Z, Lok AS, Rinaudo JA, Srivastava S, Llovet JM, Villanueva A…